[Skip to Content]
[Skip to Content Landing]
Views 1,119
Citations 0
Research Letter
September 14, 2020

Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D

Author Affiliations
  • 1Department of Medicine, University of California, San Francisco
  • 2Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo
  • 3Pacific Health Research and Education Institute, Honolulu, Hawaii
  • 4Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • 5Departments of Medicine, Health Policy, and Informatics, University of Minnesota School of Medicine, Minneapolis
  • 6Department of Family Medicine and Community Health, John A. Burns School of Medicine, University of Hawaii, Honolulu
JAMA Intern Med. Published online September 14, 2020. doi:10.1001/jamainternmed.2020.2922

Diabetes affects 1 in 3 Medicare beneficiaries.1 Treatment guidelines recommend that most patients start treatment with metformin followed by second-line drugs until glycemic goals are reached. For years, these second-line drugs were predominantly inexpensive generic drugs, such as sulfonylureas and thiazolidinediones (TZDs).2 Recent guidelines, however, endorse costly, predominantly brand-name drugs, such as sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), as preferred second-line medications for patients with established or increased risk for atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.3 Some SGLT2is and GLP-1RAs offer cardiovascular benefits, and certain SGLT2is are protective against renal disease.3 A third novel class, dipeptidyl peptidase-4 inhibitors (DPP-4is), is also increasingly used after metformin.2 Because the cost of medications affects adherence,4 we examined cost sharing for these novel diabetes agents under Medicare Part D, which covers 45 million people.5

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words